Fortis Healthcare reported strong financial results for the September 2025 quarter, with consolidated net profit rising 82% year-on-year, compared with ₹176.5 crore in the same period last year. The performance was driven by steady growth in both the hospital and diagnostics businesses.
The company’s revenue grew 17.3% year-on-year to ₹2,331.4 crore in the September quarter, supported by higher patient volumes and improved performance across key hospitals.
Operating performance also strengthened, with EBITDA increasing 28% year-on-year to ₹557 crore. EBITDA margins expanded to 24% from 22% in the corresponding quarter last year, reflecting effective cost controls and enhanced operating leverage.
The hospital business remained the primary growth driver, supported by increased inpatient volumes, elective surgeries, and a higher share of complex treatments. The diagnostics segment also saw consistent performance, benefiting from the expansion of Fortis’ laboratory network and growing demand for preventive health packages.
In a separate development, IHH Healthcare Berhad, the majority shareholder in Fortis Healthcare, announced the completion of its mandatory open offers for both Fortis Healthcare Ltd and Fortis Malar Hospitals Ltd. The completion of the open offers marks a significant step in IHH’s strategic expansion in India’s healthcare sector.
On November 12, 2025, Fortis Healthcare share price opened at ₹1,004.10, compared to the previous close of ₹986.90. During the session, the stock touched a high of ₹1,007.50 and a low of ₹949.60. At 2:14 PM IST, it was trading at ₹973.00, down by 1.41%.
The stock recorded a traded volume of 55.15 lakh shares and a traded value of ₹534.92 crore on the NSE. The market capitalisation stood at ₹73,223.39 crore. Over the past 52 weeks, Fortis Healthcare has hit a high of ₹1,104.30 and a low of ₹577.00. The stock is currently trading at a P/E ratio of 73.17.
Read More: IHH Healthcare Moves to Acquire Additional 26.1% Stake.
Fortis Healthcare delivered a strong second-quarter performance, with double-digit revenue growth and a sharp rise in profitability. Improved margins, cost efficiency, and stable demand in both hospital and diagnostics businesses contributed to the positive results. The completion of IHH Healthcare’s open offers further strengthens the company’s strategic position within India’s expanding healthcare industry.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Nov 12, 2025, 2:19 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and mutual funds, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
